Structural Heart Disease

A budget impact analysis details the benefits of TAVR compared with SAVR from the hospital payers' perspective among patients with low-risk aortic stenosis.

A new study provides insight into contemporary trends in gender- and income-based disparities in 30-day mortality risk following cardiac surgery among patients in the US.

An analysis of data from the PARTNERS trials and registries details associations between early LVEF improvement following TAVR and 5-year outcomes, including risk of all-cause and cardiovascular mortality.

A retrospective analysis of data from more than 480 LAAO procedures using the Watchman device provides insight into the benefits of preprocedural CT imaging compared to stand-alone TEE.

In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.

A new study from the Mayo Clinic provides insight into the prognostic value of mitral annulus calcification for predicting risk of mortality, regardless of whether or not patients had subsequent mitral valve dysfunction.

An analysis of data from the Cleveland Clinic Echocardiography database provides an overview of the association between the use of calcium supplements with increased risk of mortality and worsening stenosis among older patients with aortic stenosis.

A large-scale analysis of data from a pair of RCTs and a nonrandomized registry provide insight into the risk of valve deterioration seen with TAVR vs SAVR and to what extent this might influence risk of mortality.

ADAPT TAVR found use of edoxaban vs DAPT resulted in a numerical reduction in SLT, but this did not reach statistical significance and did not contribute to a reduction in stroke or cerebral lesions.

An analysis comparing 15-year outcomes following Ross procedure and biological or mechanical aortic valve replacement provides insight into the risk of mortality and other adverse outcomes associated with each procedure.

Announced on Dec. 20, the US FDA awarded approval to the Sapien 3 with Alterra from Edwards Lifesciences Corporation for pediatric and adult patients with severe pulmonary regurgitation.

Results of a recent study indicate each $1,000 decrease in median household income was associated with a 0.2% reduction in the number of TAVR procedures performed per 100,000 Medicare beneficiaries.

A recent trial found concomitant tricuspid annuloplasty could lower the risk of mortality and progression to severe tricuspid regurgitation among patients with degenerative mitral valve regurgitation.

Every year, AHA Scientific Sessions provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for late-breaking data from AHA 2021 Scientific Sessions includes AVATAR, RAPID CABG, REVERSE-IT, and more.